acff2b90.e0b8.4523.8db6.6cce367439be
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- PANCREAS_BETA_CELLS+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.350
- PROTEIN_SECRETION+0.290
- OXIDATIVE_PHOSPHORYLATION+0.260
- MTORC1_SIGNALING+0.220
- WNT_BETA_CATENIN_SIGNALING+0.210
- ANDROGEN_RESPONSE+0.200
- HYPOXIA+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.240
- FATTY_ACID_METABOLISM-0.230
- E2F_TARGETS-0.170
- MYC_TARGETS_V2-0.170
- INTERFERON_GAMMA_RESPONSE-0.160
- KRAS_SIGNALING_DN-0.150
- ALLOGRAFT_REJECTION-0.140
- ESTROGEN_RESPONSE_LATE-0.140
- TNFA_SIGNALING_VIA_NFKB-0.140
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A152-01A-11R-A12D-07 | — | C | 0.710 |
| 2 | TCGA-44-8119-01A-11R-2241-07 | — | cohortA3 | 0.700 |
| 3 | TCGA-UY-A8OC-01A-11R-A36F-07 | — | — | 0.657 |
| 4 | C3L-01838 | — | cohortSQ1 | 0.656 |
| 5 | TCGA-AQ-A0Y5-01A-11R-A14M-07 | — | C | 0.654 |
| 6 | SRR25617936 | — | E | 0.644 |
| 7 | 3cf35e3b-812f-4cc1-bd37-e78fd6af6dc4 | — | — | 0.640 |
| 8 | TCGA-CV-7416-01A-11R-2081-07 | — | — | 0.621 |
| 9 | TCGA-66-2789-01A-01R-0980-07 | — | cohortSQ1 | 0.620 |
| 10 | 20020076.Her2HRpos | — | C | 0.617 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |